http://rdf.ncbi.nlm.nih.gov/pubchem/patent/ES-2543634-T3
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_3120ae9cab5bb4831f0cc16288966367 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-50 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-04 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-50 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12P21-00 |
| filingDate | 2011-01-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2015-08-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_14f4d02f81c6c1093fba1aec13468f00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_24e0e8de5e256a651ad4f4ea24a97ba6 |
| publicationDate | 2015-08-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | ES-2543634-T3 |
| titleOfInvention | Process for preparing FGF-21 with low O-glycosylation grade |
| abstract | A process for recombinant expression of native FGF21 with SEQ ID NO: 1 and analogs thereof, said analogs of native human FGF21 being able to be deduced or derived with SEQ ID NO: 1 by modification of the amino acid sequence, said modification being substitution, deletion and / or addition of one or more amino acids, said analogs having a glucose lowering effect and having an identity with human FGF21 that is at least 95%, where the yeast used is a deactivated pmt2 strain. |
| priorityDate | 2010-01-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 69.